A box of ozmpic made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Holi adams | Roots
Novo nordisk On Monday, it was said that it now provides cash-peating American patients for less than half of its monthly list price to its blockbuster diabetes treatment ozmpic, as drug manufacturers face rising political pressure for low prices in the country.
Patients can pay $ 499 cash per month for three doses of ozmpic. They can get the price through the official website of the drug, the patient’s patient aid program and the company’s recently launched platforms. Direct-to-Consumer Online PharmacyOut of which the latter also sends injections directly to the homes of the patients.
According to a release by Drug Saving Company Goodraks, Novo Nordisk, ozmpic and its weight loss counterpart will present Vagovi for $ 499 per month for $ 499 per month, which will provide discounts in over 70,000 pharmacies.
Novo Nordisk’s cash-pay offering will expand access to patients with type 2 diabetics, who do not have insurance coverage for weekly injections. In March, company Started offering wegovy Cash-peering Americans for half of its list value.
The list value of ozmpic before insurance and other exemption is approximately $ 1,350 per month, and has been a constant target of political and public shock in recent years. The new proposal comes after the President Donald Trump Send separate letters to Novo Nordisk and 16 other drug manufacturers in July, Call them to take steps To reduce drug prices in the US amidst other suggested tasks, they urged them to adopt models that directly sell medicines to consumers or businesses.
The purpose of the efforts is to provide ozmpic and vegovi to more people, while also ensuring that patients use branded drugs instead of cheap mixed copy. Those drugs exploded in popularity during the rescued American deficiency of Semaglutide of Novo Nordisk, the active ingredient in both drugs.
While the ozmpic “is well covered in the US, let’s not forget that there are some patients who pay out-of-packets for this important drug,” Dave Moore, American operational vice president and global business development in Novo Nordisk, said in the release. “We assume that if a single patient feels the need to turn to a potentially unsafe and unpublished knockoff options, then it is a lot.”
Ellie lily Similarly, they have gone to reduce their popular obesity and diabetic drugs for patients with cash-paying. Both companies are fighting to dominate the market for so-called GLP-1s, which mimic some intestinal hormones to press hunger and regulate blood sugar.
